insights_auto
Why is FARN up 2.05%?
Dive Deeperchevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBXÂ 37.25
arrow_upward
+2.05%(+0.75) 1D
Oct 2, 4:30:00 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
GBXÂ 38.00
High
GBXÂ 38.00
Low
GBXÂ 35.09
Mkt. cap
73.90M
Avg. vol.
51.36K
Volume
35.95K
52-wk high
GBXÂ 193.58
52-wk low
GBXÂ 34.00
EPS
-GBXÂ 0.10
Shares outstanding
31.03M
No. of employees
36
Open
GBXÂ 38.00
High
GBXÂ 38.00
Low
GBXÂ 35.09
Mkt. cap
73.90M
Avg. vol.
51.36K
Volume
35.95K
52-wk high
GBXÂ 193.58
52-wk low
GBXÂ 34.00
EPS
-GBXÂ 0.10
Shares outstanding
31.03M
No. of employees
36
News stories
From web sources and news partners
AOL.com
·
1 hour ago
Forget the S&P 500: SCHD Is Beating It by Nearly 10 Points in 2026 and Its Dividend Just Grew
InteractiveCrypto
·
9 hours ago
The S&P 500 Looks Strong. Underneath, October Looks Thin.
Traders Union
·
3 hours ago
S&P500 has posted gains in nearly every November-through-June period since 1942, Lia Holmgren notes
Forbes
·
11 hours ago
S&P 500 Q3 Earnings Preview: Trends Investors Need To Watch
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy